SCHEMBL700525

SCHEMBL700525

C=CCC(=O)NN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27559866 0.79 ALDH1A1 (0.42)
SCHEMBL175574 0.77 TSHR (0.39)
SCHEMBL252883 0.77 TSHR (0.39)
SCHEMBL8291484 0.74
SCHEMBL4105322 0.74
SCHEMBL1839325 0.74
SCHEMBL5138203 0.74
SCHEMBL2744516 0.74
SCHEMBL16130339 0.72
SCHEMBL103350 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108713025-A Slave single carrier for treating the heart patient's condition and other pathology expresses the composition and method of multiple biological activities polypeptide 英特拉克森公司 2018-10-26 CN claimed
EP-3387010-A1 COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIES Intrexon Corporation (US) 2018-10-17 EP claimed
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-08-10 US claimed
WO-2017083750-A1 COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIES INTREXON CORPORATION (US) 2017-05-18 WO claimed
US-9486455-B2 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2016-11-08 US claimed
US-20160113903-A1 SirT INHIBITORS THAT BIND TO NAD ELIXIR PHARMACEUTICALS, INC. (US) 2016-04-28 US claimed
US-20150374719-A1 METHODS FOR TREATING FUNGAL INFECTIONS BRIGHAM YOUNG UNIVERSITY (US) 2015-12-31 US claimed
US-20140163029-A1 SirT INHIBITORS THAT BIND TO NAD ELIXIR PHARMACEUTICALS, INC. (US) 2014-06-12 US claimed
EP-2521548-A2 QUINAZOLIN-4(3A)-ONE DERIVATIVES AND METHODS OF USE THEREOF Proteologics, Ltd (IL) 2012-11-14 EP claimed
EP-2421858-A1 THIOXANTHENE DERIVATIVES FOR THE TREATMENT OF INFECTIOUS DISEASES BKG Pharma ApS (DK) 2012-02-29 EP claimed
WO-2004064745-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS, INC. (US) 2004-08-05 WO claimed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US claimed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO claimed
EP-0348261-B1 Radiohalogenated compounds for site specific labeling CYTOGEN CORP (US) 1993-12-15 EP claimed
US-4966999-A Radiohalogenated compounds for site specific labeling CYTOGEN CORPORATION (US) 1990-10-30 US claimed
EP-0348261-A1 Radiohalogenated compounds for site specific labeling CYTOGEN CORPORATION (US) 1989-12-27 EP claimed
WO-1989011876-A1 RADIOHALOGENATED COMPOUNDS FOR SITE SPECIFIC LABELING CYTOGEN CORPORATION (US) 1989-12-14 WO claimed
US-4464366-A Cephem compounds having a terminal aminocarboxylic acid grouping and containing an azacyclyl(thio)ureido group CIBA GEIGY CORPORATION (US) 1984-08-07 US claimed
US-4337262-A HYPOTENSIVE AGENT, ANTICOAGULANT, VASODILATION, ANTIULCER AGENT, BRONCHODILATOR AGENT, ANTIALLERGEN, AND CONTRACEPTIVE BURROUGHS WELLCOME CO. (US) 1982-06-29 US claimed